▪︎The Chairman of the Authority follows up with the General Manager of Takeda Pharmaceuticals for Egypt and the Arab Gulf countries on joint initiatives in treating tumors and rare and genetic diseases, and launching a platform to enable medical personnel to view the latest medicines and treatments
▪︎The head of the Health Care Authority appreciates the ongoing cooperation with Takeda in "establishing the first integrated oncology center at the Ismailia Medical Complex in cooperation with the British Christie-NHS."
▪︎Head of the Health Care Authority: Discussing expansion in the second phase of the project by increasing training missions and signing a cooperation agreement with NHS to follow up and evaluate the development of the Authority's oncology centers and completing the development of the oncology treatment center in Ismailia in accordance with Christie's recommendations
▪︎Head of the Healthcare Authority: International partnerships with Takeda and the British Christie Group are a major added value to the comprehensive health insurance system. What has been achieved in the field of oncology is an unprecedented achievement that has received global recognition in the annual report of the international company "Takeda."▪︎General Manager of Takeda Pharmaceuticals for Egypt and the Gulf States:Cooperation with the Healthcare Authority is a model to be emulated regionally and globally, and the inclusion of the Egyptian project in the company's annual global report reflects the success of the Egyptian experience in the field of oncology
.........................
Dr. Ahmed El-Sobky, Chairman of the Authority for Health Care, met with Dr. Khaled Sari, General Manager of Takeda Pharmaceuticals for Egypt and the Arab Gulf States, at the Authority's main headquarters in Cairo to follow up on joint initiatives in the fields of treating tumors and rare and genetic diseases in a way that enhances the Authority's strategies in expanding its advanced medical services and localizing the latest global treatment systems within Egypt.
At the beginning of the meeting, Dr. Ahmed Al-Sobki welcomed the attendees and congratulated Dr. Khaled Sari, praising the fruitful and lasting cooperation between Takeda Egypt and the Health Care Authority. During the meeting, the two sides reviewed the most prominent joint achievements in the field of oncology treatment, as Takeda contributed to the establishment of the Integrated Oncology Services Center (Integrated Practice Unit—IPU) at the Ismailia Medical Complex, in cooperation with the Christie Group of the British National Health Service Christie-NHS.
The cooperation also included a visit by the Foundation's experts to the Ismailia Medical Complex and a comprehensive evaluation, followed by the organization of intensive training programs for multidisciplinary committees with the participation of more than 15 foreign experts from the British "Christie" group. In addition to nominating medical personnel for training at the Christie's Group in Britain, which contributes to building the capabilities of Egyptian medical personnel in accordance with the latest international practices.
The meeting also discussed the expansion of the second phase of the project by increasing the number of training missions for Egyptian medical staff and supporting the signing of a cooperation agreement with the British National Health Service (NHS) to follow up and evaluate the development of oncology units in the Authority's facilities, in addition to completing the development of the oncology treatment center at the Ismailia Medical Complex in accordance with the technical recommendations of the Christie Group.
In this context, Dr. Ahmed El Sobky stressed that international partnerships with leading international entities such as Takeda and the British Christie Group represent a major added value to the comprehensive health insurance system in Egypt, stressing that what has been achieved in the field of oncology is an unprecedented achievement that has received international praise, as it was included in the annual report of the international company Takeda as the first project from Egypt to receive this recognition. He added that international partnerships have become a fundamental pillar for developing health services and transferring the latest global medical systems to Egypt.
.
He also pointed out that the Authority is working to emulate this success in the field of rare and hereditary diseases, starting from early diagnosis to treatment and awareness, with a focus on training medical personnel and building the capabilities of doctors, in addition to launching awareness campaigns targeting patients and their families, as well as forming joint working teams to develop diagnostic, treatment and education paths, and holding training workshops for doctors and scientific forums that link Egyptian medical personnel with international experts Stressing that early detection represents the biggest challenge in these diseases.
Al-Sabki added that cooperation with Takeda will extend to support the Authority's efforts to prevent some diseases such as dengue fever in the governorates of South Sinai, Luxor, and Aswan, stressing that the Authority is continuing to strengthen strategic partnerships that ensure improving the quality of health services as part of its plan to enhance public health and prevent diseases.
For his part, Dr. Khaled Sari, General Manager of Takeda Pharmaceuticals for Egypt and the Gulf States, praised the fruitful cooperation achieved with the General Authority for Healthcare, stressing that what has been achieved so far is a model to be emulated at the regional and global levels, and that the inclusion of the Egyptian project in the company's annual global report reflects the importance of the Egyptian experience and its success in the field of oncology.
Sari added, "We are proud of our strategic partnership with the Authority , and we are committed to working to develop cooperation during the coming period in the fields of rare and genetic diseases and expanding training programs and scientific missions in a way that ensures a sustainable and effective partnership that responds to the needs of the promising Egyptian market and serves the Egyptian patient first and foremost."
The meeting was attended by Takeda Egypt: Dr. Randa Adel, Head of the Marketing and Market Access Unit; Dr. Vince Nabil, Director of Communication and Public Relations; and Dr. Karim El Samra, Head of the Drug Availability Unit and Head of the Oncology File at the company.
Also present from the Authority were: Dr. Amir Al-Talwani, Executive Director of the Authority, Dr. Ahmed Hammad, Advisor to the Chairman of the Authority for Health Policies and Systems and Director General of the General Administration of Strategic Management, Dr. Wael Omran, Advisor to the Chairman of the Authority for Supply Affairs and Director General of the General Administration for Administrative Affairs, Dr. Mahmoud Al-Deeb, Assistant Executive Director for Health Planning and Mapping Affairs and Director General of the Technical Office of the Chairman of the Authority, Dr. Mustafa Shaaban, Head of the Central Administration for Health and Therapeutic Care, Dr. Radwa Abdel Azim, Head of the Oncology File at the Authority and in cooperation with Takeda Company, and Dr. Maha Saeed, Director of the Pharmacovigilance Unit at the Authority.
